AIM To understand the polymorphism distribution of SLCO1B1 and ApoE genes in Zhengzhou area and to explore the risk assessment of the use of statins.
METHODS The SLCO1B1 and ApoE genotypes in the whole blood of 1037 patients with cardiovascular and cerebrovascular diseases in the inpatient department of Henan provincincal hospital of TCM from July 2018 to July 2019 were qualitatively detected by PCR-fluorescence probe technology. The distribution characteristics of SLCO1B1 and ApoE genotypes were analyzed according to the age and the gender of the subjects, and the data of other regions were compared.
RESULTS The results showed that the I genotype (*1a/*1a+*1a/*1b+*1b/*1b), II genotype (1a/*5+*1a/*15+*1b/*15) and III genotype of SLCO1B1 in the tested population accounted for 75.6%, 22.7% and 1.6%, respectively. ApoE E2 genotype (E2/E2+E2/E3), E3 genotype (E2/E4+E3/E3) and E4 genotype (E3/E4+E4/E4) accounted for 13.6%, 70.5% and 15.9%, respectively. SLCO1B1 and ApoE genotype groups showed no significant difference in distribution between age groups and genders. Compared with patients with cardiovascular and cerebrovascular disease in Wuhan, Changsha and Guangzhou, the combination and distribution of the 2 genotypes in Zhengzhou showed no significant difference.
CONCLUSION The polymorphisms of SLCO1B1 and ApoE genes of patients with cardiovascular and cerebrovascular diseases in Zhengzhou are mainly I genotype and E3 genotype, and the combinations of the 2 genotypes are not affected by age, gender and region.
DownLoad: